,44 Routine use of renin-angiotensin system inhibitors remains foundational and expanding access to newer cardio-renoprotective therapies (sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists) is needed, particularly in regions with a rapidly growing CKD burden. This evidence concerns the gene GLP1R and chronic kidney disease.